Selective Arylation of Selenocysteine of Thioredoxin Reductase 1 by an Organogold Compound: Expanding the Tool-Box of Metal-Templated Reactions in Cancer Cells

08 September 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Cyclometalated gold(III) complexes have been reported to template C-S cross-coupling reactions in a biological environment and acting as modifiers of cysteine residues. To broaden the scope of organogold complexes for covalent protein post-translational modification in cancer cells, an oxime-containing C^N-cyclometalated gold(III) compound was synthesised featuring a carboxylic acid group for either immobilisation on amine-bearing solid support (Au), or functionalisation with a fluorescent tag (Au-Fluo). Live-cell imaging revealed that Au-Fluo distributed evenly into SW480 colon carcinoma cells, with a slight preference for the nuclear and nucleolar compartments. Thioredoxin reductase 1 (TXNRD1) was observed as the major interactor of Au from SW480 cell lysates in chemoproteomic approaches and a 2 : 1 binding stoichiometry resulted from titration-dependent pull-downs. Direct interactions confirmed a high reactivity of Au towards the catalytic CysSec-dyad at the C-terminus of TXNRD1 and revealed double arylation events at this motif. Therefore, the observed Au-templated arylation of selenocysteine likely contributes to the compound’s biological effects. Proteome profiling of SW480 cancer cells treated with sub-cytotoxic concentrations of Au revealed an apparent reduction of the available selenium pool by down-regulating the detected selenoproteins, except TXNRD1. Additionally, Au treatment induced the NRF2-KEAP1 stress response, pointing towards a disturbance of the intracellular redox balance by Au-mediated covalent targeting of TXNRD1. Inhibition of heme oxygenase-1 (HMOX1), the most strongly induced NRF2-target, showed pronounced synergism with Au treatment. Overall, organogold compounds, templating the formation of C–S(Se) bonds in cells as a novel mode of action, hold promise for the targeted modification of (onco)proteins.


metals in medicine
thioredoxin reductase 1

Supplementary materials

Supporting Information
Supporting information contains synthesis and characterisation, experimental details, supplementary figures and supplementary tables.


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.